Screener
Integra LifeSciences IART Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000917520-26-000058
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Payments for contingent considerations | (6,842) | (16,451) |
| Proceeds from exercised stock options and employee stock purchase plan | 760 | 957 |
| Cash taxes paid in net equity settlement | (1,589) | (2,361) |
| Net cash provided by financing activities | 7,479 | 14,238 |
| Effect of exchange rate changes on cash and cash equivalents | (2,586) | 17,207 |
| Net decrease in cash and cash equivalents | (20,633) | (28,461) |
| Cash and cash equivalents at beginning of period | 235,048 | 246,375 |
| Cash and cash equivalents at end of period | $214,415 | $217,914 |
Item 1. Financial Statements
FAQ
- What is Integra LifeSciences's net change in cash?
- Integra LifeSciences (IART) reported net change in cash of -$22.39M in Q2 2026.
- How has Integra LifeSciences's net change in cash changed year-over-year?
- Integra LifeSciences's net change in cash decreased by 5.7% year-over-year, from -$21.19M to -$22.39M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Integra LifeSciences's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude